CGRP receptor antagonists: all 148 studies that test it

Page 2 of 2. Open to participants first (36), then studies with results posted, then the rest; newest registration first within each.

• An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of MigraineCompletedNCT02873221Phase 3Results posted
• Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of MigraineCompletedNCT02867709Phase 3Results posted
• Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine PreventionCompletedNCT02848326Phase 2/3Results posted
• Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of MigraineCompletedNCT02828020Phase 3Results posted
• Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy FemalesCompletedNCT02792517Phase 1Results posted
• Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous SumatriptanCompletedNCT02741310Phase 1Results posted
• A Safety and Efficacy Study to Evaluate AMG 334 in Migraine PreventionCompletedNCT02630459Phase 2Results posted
• Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)CompletedNCT02575833Phase 2Results posted
• To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine PatientsCompletedNCT02542605Phase 1Results posted
• Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine PreventionCompletedNCT02483585Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine PreventionCompletedNCT02456740Phase 3Results posted
• A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.CompletedNCT02174861Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine PreventionCompletedNCT02066415Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine PreventionCompletedNCT01952574Phase 2Results posted
• Study of Erenumab (AMG 334) in Women With Hot FlashesCompletedNCT01890109Phase 1Results posted
• Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine PatientsCompletedNCT01723514Phase 1Results posted
• Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine PatientsCompletedNCT01688739Phase 1Results posted
• A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)CompletedNCT01657370Phase 2Results posted
• A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)CompletedNCT01613248Phase 2Results posted
• Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of MigraineCompletedNCT01430442Phase 2Results posted
• Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult ParticipantsCompletedNCT07680686Phase 1
• The R-E-V-I-V-A-L StudyActive, not recruitingNCT06992674Phase 2
• Acute Migraine Treatment in the ED With GepantsTerminatedNCT06985342Phase 4
• Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineActive, not recruitingNCT06806293Phase 3
• A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent MigraineActive, not recruitingNCT06616194Phase 3
• A Study to Learn How the Study Medicine Called Zavegepant is Taken Up Into Blood and Breast Milk of Healthy Breast-Feeding WomenCompletedNCT06453356Phase 1
• Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineActive, not recruitingNCT06417775Phase 3
• Investigational Use of Erenumab for the Treatment of Fibromyalgia PainWithdrawnNCT06411067Phase 3
• Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With MigraineCompletedNCT06241313Phase 3
• A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult ParticipantsWithdrawnNCT06103734Phase 3
• Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult VolunteersCompletedNCT05892757Phase 1
• Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and CapsaicinCompletedNCT05654298Not applicable
• Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodiesActive, not recruitingNCT05503082Phase 4
• Cluster Headache Treatment With RimegepantCompletedNCT05264714Phase 2
• Efficacy of Erenumab in Chronic Cluster HeadacheCompletedNCT04970355Phase 2
• Study of Intravenous Erenumab in Patients With Status MigrainosusWithdrawnNCT04920331Phase 1
• Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of MigraineCompletedNCT04818515Phase 1
• A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic MigraineCompletedNCT04686136Phase 3
• Registry for Migraine - Clinical CoreStatus unknownNCT04603976Phase 4
• The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine PatientsStatus unknownNCT04452929Not applicable
• Efficacy and Tolerability of Erenumab in the Management of Persistent Redness and Flushing in RosaceaStatus unknownNCT04419259Phase 2
• Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With ErenumabWithdrawnNCT04114630Phase 3
• Efficacy and Tolerability of Erenumab in Patients With Trigeminal NeuralgiaStatus unknownNCT04054024Phase 2
• A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine PatientsCompletedNCT03977649Phase 4
• Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persistent Post-Traumatic HeadacheCompletedNCT03974360Phase 2
• Efficacy and Safety of Erenumab in Pediatric Participants With Episodic MigraineActive, not recruitingNCT03836040Phase 3
• Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine HeadacheCompletedNCT02198339Phase 2
• Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine ConditionCompletedNCT01445067Phase 1

← CGRP receptor antagonists overview